Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
21.27
-0.19 (-0.89%)
At close: Dec 20, 2024, 4:00 PM
21.68
+0.41 (1.93%)
After-hours: Dec 20, 2024, 4:14 PM EST
Catalyst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for CPRX stock have an average target of 31.14, with a low estimate of 23 and a high estimate of 36. The average target predicts an increase of 46.40% from the current stock price of 21.27.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 18, 2024.
Analyst Ratings
The average analyst rating for CPRX stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Buy Initiates $35 | Buy | Initiates | $35 | +64.55% | Nov 18, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $30 → $36 | Strong Buy | Maintains | $30 → $36 | +69.25% | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +41.04% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $26 → $30 | Strong Buy | Maintains | $26 → $30 | +41.04% | Aug 12, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $27 → $31 | Strong Buy | Maintains | $27 → $31 | +45.75% | Aug 9, 2024 |
Financial Forecast
Revenue This Year
493.71M
from 398.20M
Increased by 23.98%
Revenue Next Year
583.92M
from 493.71M
Increased by 18.27%
EPS This Year
1.24
from 0.63
Increased by 97.25%
EPS Next Year
1.62
from 1.24
Increased by 30.37%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 511.7M | 638.5M | 746.9M | |||
| Avg | 493.7M | 583.9M | 666.0M | |||
| Low | 470.7M | 544.3M | 570.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 28.5% | 29.3% | 27.9% | |||
| Avg | 24.0% | 18.3% | 14.1% | |||
| Low | 18.2% | 10.2% | -2.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.43 | 2.07 | 2.34 | ||
| Avg | 1.24 | 1.62 | 1.98 | ||
| Low | 1.14 | 1.33 | 1.47 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 126.7% | 66.5% | 44.5% | ||
| Avg | 97.3% | 30.4% | 22.5% | ||
| Low | 80.4% | 7.3% | -9.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.